[Medical therapy of male lower urinary tract symptoms]. 2013

C Gratzke, and C G Stief
Urologische Klinik und Poliklinik, Klinikum der Universität München-Großhadern, Marchioninistraße 15, Munich, Germany. christian.gratzke@med.uni-muenchen.de

UI MeSH Term Description Entries
D008297 Male Males
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D058986 Phosphodiesterase 5 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 5. PDE-5 Inhibitor,PDE5 Inhibitor,Phosphodiesterase 5 Inhibitor,Phosphodiesterase Type 5 Inhibitor,PDE-5 Inhibitors,PDE5 Inhibitors,Phosphodiesterase Type 5 Inhibitors,5 Inhibitor, Phosphodiesterase,Inhibitor, PDE-5,Inhibitor, PDE5,Inhibitor, Phosphodiesterase 5,Inhibitors, PDE-5,Inhibitors, PDE5,Inhibitors, Phosphodiesterase 5,PDE 5 Inhibitor,PDE 5 Inhibitors
D059411 Lower Urinary Tract Symptoms Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM. Lower Urinary Tract Symptom
D018680 Cholinergic Antagonists Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. Acetylcholine Antagonist,Acetylcholine Antagonists,Anti-Cholinergic,Anticholinergic,Anticholinergic Agent,Anticholinergic Agents,Cholinergic Receptor Antagonist,Cholinergic-Blocking Agent,Cholinergic-Blocking Agents,Cholinolytic,Cholinolytics,Anti-Cholinergics,Anticholinergics,Cholinergic Antagonist,Cholinergic Receptor Antagonists,Agent, Anticholinergic,Agent, Cholinergic-Blocking,Agents, Anticholinergic,Agents, Cholinergic-Blocking,Antagonist, Acetylcholine,Antagonist, Cholinergic,Antagonist, Cholinergic Receptor,Antagonists, Acetylcholine,Antagonists, Cholinergic,Antagonists, Cholinergic Receptor,Anti Cholinergic,Anti Cholinergics,Cholinergic Blocking Agent,Cholinergic Blocking Agents,Receptor Antagonist, Cholinergic,Receptor Antagonists, Cholinergic

Related Publications

C Gratzke, and C G Stief
June 2022, Aktuelle Urologie,
C Gratzke, and C G Stief
January 2011, Current opinion in urology,
C Gratzke, and C G Stief
November 2007, International journal of clinical practice,
C Gratzke, and C G Stief
December 2013, Current urology reports,
C Gratzke, and C G Stief
April 2017, European urology,
C Gratzke, and C G Stief
January 2009, Reviews in urology,
C Gratzke, and C G Stief
November 2008, BJU international,
C Gratzke, and C G Stief
September 2003, Connecticut medicine,
C Gratzke, and C G Stief
January 2013, International journal of urology : official journal of the Japanese Urological Association,
C Gratzke, and C G Stief
September 2022, Panminerva medica,
Copied contents to your clipboard!